Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44–51.

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47.

Article  PubMed  Google Scholar 

Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov. 2021;16(2):125–34.

Article  CAS  PubMed  Google Scholar 

Tang JT, Mao YM. Development of new drugs for the treatment of nonalcoholic steatohepatitis. J Dig Dis. 2020;21(1):3–11.

Article  PubMed  Google Scholar 

Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(4):367–78.

Article  CAS  PubMed  Google Scholar 

Brown E, Heerspink H, Cuthbertson DJ, Wilding J. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262–76.

Article  CAS  PubMed  Google Scholar 

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24.

Article  CAS  PubMed  Google Scholar 

Newsome PN, et al. Phase 3 ESSENCE Trial: semaglutide in metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl. 11):6–7.

Google Scholar 

Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023;8(2):120–32.

Article  CAS  PubMed  Google Scholar 

Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2023;29(7):1782–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-Alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne). 2020;11:601290.

Article  PubMed  Google Scholar 

Pan Q, Lin S, Li Y, Liu L, Li X, Gao X, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra A, Sarangi SC, Reeta K. First-in-human dose: current status review for better future perspectives. Eur J Clin Pharmacol. 2020;76(9):1237–43.

Article  PubMed  Google Scholar 

Han W, Yang S, Xiao H, Wang M, Ye J, Cao L, et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int J Mol Sci. 2022;23(24):15627-15646.

Article  Google Scholar 

Hui X, Feng T, Liu Q, Gao Y, Xu A. The FGF21-adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol. 2016;8(2):110–9.

Article  CAS  PubMed  Google Scholar 

Kuritzky L, Umpierrez G, Ekoé JM, Mancillas-Adame L, Landó LF. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126(6):60–72.

Article  PubMed  Google Scholar 

Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–33.

Article  CAS  PubMed  Google Scholar 

Snitker S, Andersen A, Berg B, van Marle S, Sparre T. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: a randomized, double-blind trial in healthy subjects. Diabetes Obes Metab. 2021;23(6):1415–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Zhang Y, Li Y, Zhao X, Zhou W, Loghin C, et al. Pharmacokinetics, pharmacodynamics, and safety of dulaglutide after single or multiple doses in Chinese healthy subjects and patients with T2DM: a randomized, placebo-controlled, phase I study. Adv Ther. 2022;39(1):488–503.

Article  CAS  PubMed  Google Scholar 

Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080–93.

Article  CAS  PubMed  Google Scholar